Medlab Clinical Limited (MDC.AX)

0.0550 -0.0020 (-3.51%) At close: 04:10PM AEST

Medlab Clinical Limited

Building A
Unit A5 – A6, Botany Quarter 11-13 Lord Street
Botany, NSW 2019
Australia
61 2 8188 0311
https://www.medlab.co

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sean Michael Hall	MD, CEO & Director	492.77k	N/A	N/A
Mr. Kerem Kaya	CFO, COO & Company Sec.	82.69k	N/A	N/A
Mr. Ian Curtinsmith	Chief Information Officer	208.39k	N/A	N/A
Dr. Luis Vitetta BSc(Hons), Grad Dip, Grad Dip Nutr, Ph.D.	Director of Medical Research	278.28k	N/A	N/A
Dr. David A. Rutolo ­ (USA), J.D., Ph.D.	Director of Science	183.97k	N/A	N/A
Mr. Tony Potter	Head of Pharmaceuticals	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oro–buccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiring–bone–pain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients. In addition, it offers vitamins and supplements; and virtual clinic services. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.

Corporate governance

Medlab Clinical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.